Reversal of doxorubicin-induced vascular dysfunction by resveratrol in rat thoracic aorta: Is there a possible role of nitric oxide synthase inhibition?

Anadolu Kardiyoloji Dergisi

Volumn 9, Issue 4, 2009, Pages 260-266

  Olukman, Murat ^a   Can, Cenk ^a   Erol, Ayşe ^a   Öktem, Gülperi ^a   Oral, Onur ^b   Çinar, Mehtap Gülcihan ^a  

^a EGE UNIVERSITY   (Turkey)

^b Konak Gültepe Center for Family Planning   (Turkey)

Author keywords

Doxorubicin; Nitric oxide; Rat; Resveratrol; Vascular endothelial function

Indexed keywords

ACETYLCHOLINE; ADRIABLASTINA FLACON; CALCIMYCIN; CALCIUM IONOPHORE; DOXORUBICIN; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; RESVERATROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; HEART MUSCLE CONTRACTILE FORCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; THORACIC AORTA;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; AORTA, THORACIC; DOXORUBICIN; DRUG ANTAGONISM; ENDOTHELIUM, VASCULAR; IMMUNOHISTOCHEMISTRY; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PROSPECTIVE STUDIES; RANDOM ALLOCATION; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; STILBENES;

EID: 70349394453     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Lefrak EA, Pitha J, Rosenheim S, Gotlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32: 302-14.
2. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am J Med 1978; 65: 823-32.
3. Murata T, Yamawaki H, Hori M, Ozaki H, Karaki H. Chronic vascular toxicity of doxorubicin in an organ-cultured artery. Br J Pharmacol 2001; 132: 1365-73.
4. Wu S, Ko Y, Teng MS, Ko YL, Hsu LA, Hsueh C, et al. Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies. J Mol Cell Cardiol 2002; 34: 1595-607.
5. Wolf MB, Baynes JW. The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim Biophys Acta 2006; 1760: 267-71.
6. Vasquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA Jr, Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 1997; 36: 11293-7.
7. Duquaine D, Hirsch GA, Chakrabarti A, Han Z, Kehrer C, Brook R, et al. Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase. Vasc Med 2003; 8: 101-7.
8. Kalivendi WSV, Kotamraju S, Zhaao H, Joseph J, Kalyanaraman B. Doxorubicin-induced Apoptosis Is Associated with Increased Transcription of Endothelial Nitric-oxide Synthase. J Biol Chem 2001; 276: 47266-77.
9. Soleas GJ, Diamandis E, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin Biochem 1997; 30: 91-113.
10. Fremont L. Biological effects of resveratrol. Life Sci 2000; 66: 663-73.
11. Ray PS, Maulik G, Cordis GA, Bertelli AAE, Bertelli A, Das DK. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic Biol Med 1999; 27: 160-9.
12. Hattori R, Otani H, Maulik N, Das DK. Pharmacological preconditioning with resveratrol: a role of nitric oxide. Am J Physiol Heart Circ Physiol 2002; 282: H1988-95.
13. Rezk YA, Balulad SS, Keller RS, Bennett JA. Use of Resveratrol to improve the effectiveness of cisplatin and doxorubicin: Study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol 2006; 194: e23-e26.
14. Yu BB, Han XZ, Lou HX. Oligomers of resveratrol and ferulic acid prepared by peroxidase-catalysed oxidation and their protective effects on cardiac injury. J Agric Food Chem 2007; 55: 7753-7.
15. Nwankola RN, West WL. Inhibition of alpha-tocopherol and calcium calmodulin-stimulated phosphodiesterase activity in vitro by anthracyclines. Clin Exp Pharmacol Physiol 1988; 15: 805-14.
16. Moncada S, Palmer RMJ, Higgs EAA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-42.
17. Egleme C, Godfraind T, Miller RC. Enhanced responsiveness of rat isolated aorta to clonidine after removal of endothelial cells. Br J Pharmacol 1984; 81: 16-21.
18. Tsai S-H, Lin-Shiau S-Y, Lin J-K. Suppression of nitric oxide synthase and the down-regulation of the activation of NFκB in macrophages by resveratrol. Br J Pharmacol 1999; 126: 673-80.
19. Bi XL, Yang JY, Dong YX, Wang JM, Cui YH, Ikeshima T, et al. Resveratrol inhibits nitric oxide and TNF-α production by lipopolysaccharide-activated microglia. Int Immunopharmacol 2005; 5: 185-93.
20. Hsieh TC, Juan G, Darzynkiewicz Z, Wu JM. Resveratrol increases nitric oxide synthase, induces accumulation of p53 and P21 WAF1/CIP1, and suppresses cultured bovine pulmonary artery endothelial cell proliferation by pertubing progression through S and G2. Cancer Res 1999; 59: 2596-601.
21. Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002; 106: 1652-8.
22. Rush JWE, Quadrilatero J, Levy AS, Ford RJ. Chronic resveratrol enhances endothelium-dependent relaxation but does not alter eNOS levels of aorta of spontaneously hypertensive rats. Exp Biol Med 2007; 232: 814-22.
23. Neilan TG, Blake SL, Ichinose F, Raher MJ, Buys ES, Jassal DS, et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007; 116: 506-14.
24. Pacher P, Liaudet L. Bai P, Mabley JG, Kaminski PM, Virág Li et al. Potent metalloporphyrin peroxynitrite decomposition catalyst protect against the development of doxorubicin-induced cardiac dysfunction. Circulation 2003; 107: 896-904.
25. Liu B, Li H, Qu H, Sun B. Nitric oxide synthase expressions in ADR-induced cardiomyopathy in rats. J Biochem Mol Biol 2006; 6: 759-65.